Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin
Isabelle Gouin‐Thibault(Délégation Paris 5), Marie‐Anne Loriot(Unknown), Virginie Siguret(Délégation Paris 5), Michel Azizi(Inserm), Pascale Gaussem(Inserm), Xavier Delavenne(Centre Hospitalier Universitaire de Saint-Étienne), Céline Narjoz(Université Paris Cité), Joe‐Elie Salem(Inserm), Anne Blanchard(Délégation Paris 5), Christian Funck‐Brentano(Sorbonne Université), Patrick Mismetti, Philippe Beaune(Inserm)
Cited by 140
Related Papers
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Guidelines on the management of valvular heart disease (version 2012)
|European Heart Journal|2012|3.6k
ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
|European Heart Journal|2011|3.5k
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
|New England Journal of Medicine|2009|2.6k